

demonstrated, and the composition is able to induce a late phase response in an individual possessing the given MHC Class II molecule. The invention relates further to a peptide useful as an immunotherapeutic agent for desensitizing a patient to a polypeptide allergen, wherein the peptide is selected by a method comprising selecting a candidate peptide derived from the polypeptide allergen; determining whether the candidate peptide demonstrates restriction to a MHC Class II molecule, and determining whether the candidate peptide is able to induce a late phase response in an individual who possesses the MHC Class II molecule.

Please replace the paragraph extending from page 49, line 28 to page 50, line 5 with the following paragraph.

The following is a list of known allergen sequences and database accession numbers (NCBI Entrez accession numbers). NCBI is the National Center for Biotechnology Information and is a division of the US National Institutes of Health. The NCBI database is on the World Wide Web at ncbi.nlm.nih.gov/. The allergens may be used as described above in order to identify MHC-restricted peptides capable of inducing LPR in individuals who possess a particular MHC molecule.

Amendments to the specification are indicated in the attached "Marked Up Version of Amendments".

In the Claims

Please **cancel** claims 1-7, 10, 12, 17-23, 25, and 26-31.

Please **replace** Claims 16 and 24 with the following claim:

... a composition according to any one of Claims 8 or 9, or a pharmaceutical preparation according to Claim 11, wherein the polypeptide allergen is a fragment of Fel d I selected from the group consisting of SEQ ID Nos. 1, 2, and 3, or the composition contains the soluble MHC Class II